5 October
6 October
7 October
8 October
5 October
|
HALLS |
HEMATOLOGY PROGRAM |
|
||
|
13.00 - 13.10 |
OPENING REMARKS OF EHOC 2022 - GIUSEPPE SAGLIO - BİROL GÜVENÇ - SERDAR BEDİİ OMAY |
|||
|
13.10 - 13.40 |
OPENING LECTURE - Can Immune Therapy Cure AML? - Robert Gale |
Chair: Serdar Bedii Omay |
|
|
|
SESSION 1: Low Grade NHLs (Turkey & Macedonia & Croatia & Serbia) |
Chairs: Burhan Ferhanoglu - Rajko Kusec |
|
||
|
13.40 - 14.00 |
Chemotherapy-Free Approach in the Treatment of Follicular Lymphoma |
Ozan Salim(Virtual) |
|
|
|
14.00 - 14.20 |
How I Treat MALT Lymphomas |
Irina Panovska |
|
|
|
14.20 - 14.40 |
How I Treat Nodal and Splenic Marginal Zone Lymphoma? |
Tayfur Toptaş |
|
|
|
14.40 - 15.00 |
How I Treat Waldenstrom Disease? |
Nebojsa Andjelkovic(Virtual) |
|
|
|
15.00 - 15.20 |
General Discussion Chair: Hüseyin Saffet Beköz |
|
||
|
15.20 - 15.50 |
 SATELLITE SYMPOSIUM |
|
||
|
|
||||
|
15.50 - 16.20 |
COFFEE BREAK |
|
||
|
|
||||
|
SESSION 2 - High-Grade NHLs (Turkey and Azerbaijan) |
Chairs: Burhan Ferhanoglu - George Janossy |
|
||
|
16.20 - 16.40 |
Treatment of R/R DLBCL in Transplant Ineligible Patients |
Tayfur Toptaş |
|
|
|
16.40 - 17.00 |
BV Versus Cheq-Point Inhibitors? Which One? When? Why Should Be Perefered? |
Murat Özbalak |
|
|
|
17.00 - 17.20 |
Treatment of Mantle Cell Lymphoma in Transplant Non-Eligible Patients |
Valeh Huseynov |
|
|
|
17.20 - 17.40 |
How I Treat Double-Hit Lymphoma and High Grade B Cell Lymphoma (NOS)? |
Carmino De Souza |
|
|
|
17.40 - 18.00 |
General Discussion Chair: Olga Meltem Akay |
|
||
|
SESSION 3 - SOHO 2022 Updates and Highlights |
CHAIRS: Hagop Kantarjian(Virtual) - Mehmet Ali Özcan |
|||
|
18.00 - 18.20 |
SOHO State of the Art & Next Questions: AML |
Hagop Kantarjian(Virtual) |
||
|
18.20 - 18.40 |
SOHO State of the Art & Next Questions: ALL |
Elias Jabbour(Virtual) |
||
|
18.40 - 19.00 |
SOHO State of the Art & Next Questions: MDS |
Guillermo Garcia Manero(Virtual) |
||
|
19.00 - 19.20 |
SOHO State of the Art & Next Questions: CLL |
Susan O’Brien(Virtual) |
||
|
19.20 - 19.40 |
General Discussion Chair: Hakan Göker |
|||
6 October
|
HALLS |
HEMATOLOGY PROGRAM |
|
||
|
07.20 - 08.10 |
ORAL PRESENTATION SESSION 1 |
|||
|
07:20 - 07.30 |
A RARE Presentatıon Of Systemic Al Amyloıdosis; Pulmonary Al Amyloidosis |
Simge Erdem |
|
|
|
07.30 - 07.40 |
Treatment of a Patıent Diagnosed wıth Erdheım Chester’s Dısease in Cooperatıon with Plastıc Surgery and Hematology |
Simge Erdem |
|
|
|
07.40 - 07.50 |
Coronavirus Anxıety Level and Covıd 19 Vaccıne Attitude Among Hematologıcal Malıgnancy Patıents |
Zeynep Tuğba Güven |
|
|
|
07.50 - 08.00 |
Evaluation of MRD-status in post-induction period in pediatric patients with acute lymphoblastic leukemia |
Timur Valiev |
|
|
|
SESSION 4 - MPNs |
CHAIRS: Tariq Mughal(Virtual) - Mehmet Yılmaz |
|
||
|
08:20 - 08.40 |
Treatment Landscape in Myelofibrosis |
Daniela Cilloni |
|
|
|
08.40 - 09.00 |
Interferons in MPNs |
Selami Koçak Toprak |
|
|
|
09.00 - 09.20 |
Moleculer Profiling of MPN |
Tariq Mughal(Virtual) |
|
|
|
09.20 - 09.40 |
PV New Guidelines |
Tiziano Barbui |
|
|
|
09.40 - 10.00 |
General Discussion Chair: Mehmet Yılmaz |
|
||
|
10.00 - 10.30 |
COFFEE BREAK |
|
||
|
|
||||
|
SESSION 5 - ALL (ABHH) |
CHAIRS: Carmino De Souza - Osman İlhan - José Francisco Comenalli Marques Junior |
|
||
|
10.30 - 10.50 |
Update on ALL Therapy in 2022: How Should Be Treated |
Dieter Hoelzer |
|
|
|
10.50 - 11.10 |
Management of Ph-positive and Ph-like ALL in 2022 |
Robin Foà(Virtual) |
|
|
|
11.10 - 11.30 |
Ph+ ALL in Brazil |
Wellington Fernandes da Silva Jr.(Virtual) |
|
|
|
11.30 - 11.50 |
How To Perform Precision Medicine in South America: The Example of ALL |
Eduardo Rego(Virtual) |
|
|
|
11.50 - 12.10 |
|
|
||
|
12.10 - 12.40 |
 SATELLITE SYMPOSIUM |
|
||
|
|
||||
|
12.40 - 13.40 |
LUNCH BREAK |
|
||
|
|
||||
|
SESSION 6 - MULTIPLE MYELOMA (Greece and Italy) |
CHAIRS: Evangelos Terpos(Virtual) - Claudio Cerchione |
|
||
|
13.40 - 13.55 |
Smoldering Myeloma: To Treat or Not to Treat? |
Maria Victoria Mateos(Virtual) |
|
|
|
13.55 - 14.10 |
What is the Optimal Frontline Therapy for High-Risk Myeloma? |
Angelo Maiolino |
|
|
|
14.10 - 14.25 |
How I Treat Relapsed/Refractory Multiple Myeloma: Road to the Target Therapy |
Claudio Cerchione |
||
|
14.25 - 14.40 |
Vaccination Against SARS-CoV-2 for Myeloma Patients: Do We Need a Booster Dose and How Frequent? |
Evangelos Terpos(Virtual) |
||
|
14.40 - 14.55 |
Prognostic Factors in Multiple Myeloma: Do We Need a New ISS? |
Moshe Gatt |
||
|
14.55 - 15.20 |
General Discussion Chair: Ayşe Tülin Tuğlular |
|||
|
SESSION 7 - CLL (Middle East Societies) |
CHAIRS: Ahmad Ibrahim - Sevgi Kalayoğlu Beşışık |
|||
|
15.20 - 15.40 |
New Insights into CLL Pathogenesis |
Carlo Croce |
||
|
15.40 - 16.00 |
Firstline Treatment of CLL |
Ahmad Ibrahim |
||
|
16.00 - 16.20 |
Treatment of R/R CLL |
Ahmad Alaskar |
||
|
16.20 - 16.40 |
MRD in CLL |
Tamar Tadmor |
||
|
16.40 - 17.00 |
General Discussion Chair: Erdal Kurtoğlu |
|||
|
17.00 - 17.30 |
COFFEE BREAK |
|
||
|
SESSION 8 - SOHO ITALY |
CHAIRS: Claudio Cerchione - Giuseppe Saglio - Seçkin Çağırgan |
|||
|
17.30 - 17.45 |
SOHO Italy State of the Art & Next Questions: MM |
Claudio Cerchione |
||
|
17.45 - 18.00 |
SOHO Italy State of the Art & Next Questions: ALL and AML |
Giovanni Martinelli(Virtual) |
||
|
18.00 - 18.15 |
SOHO Italy Next future: ALL and AML |
Daniela Cilloni |
||
|
18.15 - 18.30 |
SOHO Italy State of the Art & Next Questions: CML |
Giuseppe Saglio |
||
|
18.30 - 18.45 |
General Discussion Chair: Şehmus Ertop |
|||
|
18.45 - 19.35 |
POSTER PRESENTATIONS SESSION |
|
||
| An Unusual Ocular Lymphoma, Primary Intravitreal Lymphoma Diagnosed Incidentally | Nur Seda İbili Çetinkaya | |||
| Eculizumab Dose Adjustments During Pregnancies in Paroxysmal Nocturnal Hemoglobınurıa: A Single Center Experience. | Semra Aydın | |||
| Evaluation and Management of Thyroid Nodules At a Tertiary Care Pediatric Cancer Center in Turkey | Seda Şahin | |||
| Follow-Up Of Chronic Myeloid Leukemia Patients Whose Tyrosine Kinase Treatment Was Stopped: Case Series | Kemal Fidan | |||
| Glomerular Microangıopathy with Marked Systemic Thrombotic Microangıopathy Shortly After Bortezomib in a Newly Diagnosed Poems Syndrome Patient | Tarık Onur Tiryaki | |||
| Long-Term Outcomes Of Patıents Treated wıth Caplacizumab For Immune-Mediated Thrombotic Thrombocytopenic Purpura (ITTP): The Post-Hercules Study | Özgür Pektaş | |||
| Prevention Can be the Best Tool For Adult T-Cell Leukemia. Updated T-Cell Brazil Project | Carmino De Souza | |||
| Quality of Life in Hematological Patients in the Post-Covid Era | Weronika Lebowa | |||
| Rectal Cancer Distance to the Anal Verge and the T Staging: Magnetic Resonance Imaging Findings | Najat Amar | |||
| Relapsed Mantle Cell Lymphoma with Isolated Central Nervous System Involvement That Treated with Ibrutinib; A Case Report and Lıterature Review | Pınar Tığlıoğlu | |||
| Rituximab Induced Lung Disease in a Mantle Cell Lymphoma Patient Receıving Maintenance: Case Presentation | Fehmi Hindilerden | |||
| Rituximab-Induced Severe Acute Thrombocytopenıa in a Patient with Splenic Marginal Zone Lymphoma | Taha Ulutan Kars | |||
| The Diversıty of Presentation and Management of Subcutaneous Panniculitis –Like T-Cell Lymphoma with Assocıated Hemophagocytic Syndrome - Case Series Analysis. | Justyna Jedras | |||
| The Relationship Between Ferritin Level and Thrombosis in Patıents with Difuse Large B-Cell Lymphoma | Buğra Sağlam | |||
| Vitamin B 12 Deficiency Mimicking Thrombotic Microangıopathy: A Case Report | Müzeyyen Aslaner Ak | |||
| Is There Any New Prognostic Score For Peripheral T-Cell Lymphoma? | Derviş Murad Akkurt | |||
| HBH Disease and Systemic Lupus Erythematosus | Nuray Mammadova | |||
| The Successful Major Surgery in a Patient with Inherited FVII Defıciency and a Huge Nasopharyngeal Angıofibroma | Ayşegül Ünüvar | |||
| Assocıation of NF-1 and Moyamoya Syndrome : Case Report | Şifa Şahin | |||
| Serum Total Oxidant and Antıoxidant Status in Children with Cancer | Yasin Yılmaz | |||
| Succınate Dehydrogenase Subunit B Deficient Pediatric Gist | Melek Yaman Ortaköylü | |||
| Trametinib Experıence in A Braf P.N 486 _P490del Mutation Positive Langerhans Cell Histıocytosis | Sevim Gencel Karaaslan | |||
7 October
|
HALLS |
HEMATOLOGY PROGRAM |
|
||
|
07.20 - 07.30 |
ORAL PRESENTATION SESSION 3 |
|||
|
07.20 - 07.30 |
TREATMENT-FREE REMISSION IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: MANAGEMENT APPROACHES |
Vasile Musteata(Virtual) |
|
|
|
07.30 - 07.40 |
Intrapleural Therapy to Disrupt Il-6/Il-8 Juxtactine Sıgnalling to Block Tumor Emt -and to Drıve Systemic Anti-Tumor Immunity |
Vera Donnenberg |
|
|
|
07.40 - 07.50 |
Low Incidence of Central Nervous System (CNS) Relapse of Diffuse Large B-Cell Lymphoma Despite Limited Use of Intrathecal Prophylaxis |
Aamer Aleem(Virtual) |
|
|
|
07.50 - 08.00 |
The Acute Lymphoblastıc Leukemia of Down Syndrome |
Mehmet Sezgin Pepeler |
||
|
Session 9 - CML (ELN Network) |
CHAIRS: Giuseppe Saglio - Mehmet Turgut |
|
||
|
08.20 - 08.35 |
Updates in CML Treatment |
Pia Raanani(Virtual) |
|
|
|
08.35 - 08.50 |
Third Line Therapy for Resistant and Intollerante Patients |
Andreas Hochhaus(Virtual) |
|
|
|
08.50 - 09.05 |
Molecular Monitoring in CML Patients Who Discontinue the TKI Therapy: Minimum Requirements |
Naeem Chaundri |
|
|
|
09.05 - 09.20 |
How to Deal with Comorbidities in CML Patients |
Mohamed Yassin(Virtual) |
|
|
|
09.20 - 09.35 |
CML Blast Crises Therapy |
Tomasz Sacha(Virtual) |
|
|
|
09.35 - 10.00 |
General Discussion Chair: Deniz Sargın |
|
||
|
10.00 - 10.30 |
COFFEE BREAK |
|
||
|
|
||||
|
SESSION 10 - PERSPECTIVES OF ALLOTRANSPLANT in MYELOID NEOPLASIAS (ROHS) |
CHAIRS: Elena Morzova - Ali Ünal |
|
||
|
10.30 - 10.50 |
Role of AlloHSCT in Therapy of BC CML |
Elena Morozova |
|
|
|
10.50 - 11.10 |
Results of HSCT in Primary and Secondary MDS |
Nikolay Tsvetkov |
|
|
|
11.10 - 11.30 |
Bridge Therapy with Ruxolitinib Before Allo HSCT in MF Patients |
Maria Barabanshikova(Virtual) |
|
|
|
11.30 - 11.50 |
Optimal Time for Allo HSCT in AML |
Anna Smirnova |
|
|
|
11.50 - 12.10 |
General Discussion Chair: Mehmet Yılmaz |
|
||
|
12.10 - 12.40 |
 SATELLITE SYMPOSIUM |
|
||
|
|
||||
|
12.40 - 13.40 |
LUNCH BREAK |
|
||
|
|
||||
|
SESSION 11 - BONE MARROW TRANSPLANTATION (EBMT) |
CHAIRS: Anna Sureda(Virtual) - Nilgün Sayınalp |
|
||
|
13.40 - 14.00 |
Reduced Intense Conditioning for Allogeneic Stem Cell Transplantation in AML |
Arnon Nagler(Virtual) |
||
|
14.00 - 14.20 |
FLT3 Mutated AML: Prevention and Treatment of Post-Transplant Relapse |
Ali Bazarbahchi |
||
|
14.20 - 14.40 |
Haploidentical Stem Cell Transplantation in AML; Impact of Graft Versus Host Disease Prophylaxis |
Giorgia Battipaglia(Virtual) |
||
|
14.40 - 15.00 |
The Role of Second Allogeneic Stem Cell Transplantation in Patients with Relapsed/Refractory Acute Myelogenous Leukemia |
Fabio Ciceri(Virtual) |
||
|
15.00 - 15.20 |
General Discussion Chair: Zafer Gülbaş |
|||
|
SESSION 12 - AML (SMOP) |
CHAIRS: Munira Moosajee - Berksoy Şahin |
|||
|
15.20 - 15.40 |
The landscape of AML (Non-Transplant) |
Munira Moosajee |
||
|
15.40 - 16.00 |
Transplant Indications and Strategies in AML |
Raheel Iftikhar |
||
|
16.00 - 16.20 |
New Vulnerable Targets in AML |
Giovanni Martinelli(Virtual) |
||
|
16.20 - 16.40 |
Treatment of AML in Elderly and Fragile Patients |
Alessandro Isidori |
||
|
16.40 - 17.00 |
General Discussion Chair: Orhan Ayyıldız |
|||
|
17.00 - 17.30 |
COFFEE BREAK |
|
||
|
17.30 - 18.00 |
 SATELLITE SYMPOSIUM |
|
||
|
|
||||
|
SESSION 13 - MDS (Israel Society of Hematology) |
CHAIRS: Moshe Mittelman - Mustafa Çetiner |
|||
|
18.00 - 18.20 |
MDS 2022: Yesterday - Today and Tomorrow |
Moshe Mittelman |
||
|
18.20 - 18.40 |
Has There Been Real Improvements in the Treatment of MDS |
Charles Schiffer(Virtual) |
||
|
18.40 - 19.00 |
Hereditary Bone Marrow Failure Syndromes |
Drorit Merkel(Virtual) |
||
|
19.00 - 19.20 |
Lessons from the European and Israel National MDS Registry |
Galia Stemer |
||
|
19.20 - 19.40 |
Invasive Fungal Infections in MDS Patients |
Sesin Kocagöz |
||
|
19.40 - 20.00 |
General Discussion Chair: Mustafa Nuri Yenerel |
|||
8 October
|
HALLS |
HEMATOLOGY PROGRAM |
|
||
|
07.20 - 08.10 |
ORAL PRESENTATION SESSION 5 |
|||
|
07:20 - 07.30 |
An Updated of Pioneer Project to Collect Data of T-Cell NHL Patients Among Five Regions of Brazil. T-Cell Brazil Project |
Carmino De Souza |
|
|
|
07.30 - 07.40 |
Updated Progression-Free Survival (Pfs) and Depth of Response in Ikema, a Randomized Phase 3 Trial of Isatuximab, Carfilzomib and Dexamethasone (ISA-KD) Vs KD in Relapsed Multiple Myeloma (MM) |
Özgür Pektaş |
|
|
|
07.40 - 07.50 |
Immunophenotypic Features Of Molecular Subtypes Of Breast Cancer |
Svetlana Chulkova(Virtual) |
|
|
|
07.50 - 08.00 |
Real-Life Study of Bio-Clinical Follow-Up After Bnt162b2 Mrna Covid-19 (BNTVC) Vaccination İn 235 Patients (PTS) İncluding 225 With Hematological Malignancies (HM). |
Jean Francois Rossi |
||
|
SESSION 14 - PNH AND ANTITHROMBOTIC THERAPY |
CHAIRS: Drew Provan - Mehmet Sönmez |
|
||
|
08.20 - 08.35 |
Emerging Data for Cancer Associated Thrombosis |
Piera Sivera |
|
|
|
08.35 - 08.50 |
Thrombo-inflamation in MPN's |
Alessandro Lucchessi |
|
|
|
08.50 - 09.05 |
Vascular Diseases in PNH |
Hanan Hamed |
|
|
|
09.05 - 09.20 |
How Will We Manage ITP After The Pandemic? |
Drew Provan |
|
|
|
09.20 - 09.35 |
How We (will) Treat PNH? |
Semra Aydın |
|
|
|
09.35 - 10.00 |
General Discussion Chair: Fahri Şahin |
|
||
|
10.00 - 10.30 |
COFFEE BREAK |
|
||
|
|
||||
|
10.30 - 11.00 |
  SATELLITE SYMPOSIUM |
|
||
|
|
||||
|
SPECIAL LECTURE |
Chairs: Albert Donnenberg - Birol Güvenç |
|
||
|
11.00 - 11.30 |
The Future of Engineered T-Cell Therapeutics |
Bruce Levine(Virtual) |
|
|
|
SESSION 15 - CELLULAR THERAPY IN CANCER |
Chairs: Nikolay Tupitsyn |
|
||
|
11.30 - 11.50 |
From Allogenic Transplantation to Precision Immune Therapy |
Jean Francois Rossi |
|
|
|
CELLULAR THERAPY: CAR T-CELLS IN HEMATOLOGICAL MALIGNANCIES |
Chairs: Jean Francois Rossi |
|
||
|
11.50 - 12.10 |
European Experience from Barcelona – In-House Preparation and Clinical Results |
Manel Juan |
|
|
|
12.10 - 12.30 |
Chinese Experience Tumor Burden and CAR-T Cell-Derived IL-6: Predictive Value in R/R B-ALL |
Wu Depei Suzhou(Virtual) |
|
|
|
12.30- 12.50 |
USA Experience: IN-HOUSE Preparation: Prospects and Problems |
Albert Donnenberg |
||
|
OTHER MODALITIES OF CELLULAR THERAPY |
Chairs: Vera Donnenberg |
|||
|
12.50- 13.10 |
Intrapleural Therapy To Drive Systemic Anti-Tumor Immunity |
Vera Donnenberg |
||
|
13.10- 13.30 |
Generating Not Genetically-Modified, Car-Like, NK Cells |
Martin Villalba |
||
|
13.30 - 13.50 |
Round Table: Present and Future of Cellular Therapy From Bench to Bedside |
Chairs: Jean Francois Rossi - Oral Nevruz |
||
|
13.50 - 14.10 |
CLOSING REMARKS OF EHOC 2022 |
|||